Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization

Molecular Cytogenetics

Volumn 4, Issue 1, 2011, Pages

  Wang, Y K ^a   Gao, C F ^a   Yun, T ^a   Chen, Z ^a   Zhang, X W ^a   Lv, X X ^a   Meng, N L ^a   Zhao, W Z ^a  

^a 150 Central Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CORRELATION ANALYSIS; EGFR GENE; ERBB 2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA;

EID: 79960792681     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-4-14     Document Type: Article

References (17)

1. The complexity of targeting EGFR signaling in cancer: from expression to turnover. S Sebastian J Settleman SJ Reshkin A Azzariti A Bellizzi A Paradiso, Biochim Biophys Acta 2006 1766 120 39 16889899 (Pubitemid 44175636)
2. Identification of novel nuclear localization signal within the ErbB-2 protein. QQ Chen XY Chen YY Jiang J Liu, Cell Res 2005 15 504 10 10.1038/sj.cr.7290320 16045813 (Pubitemid 41653921)
3. Integration of EGFR inhibitors with radiochemotherapy. MK Nyati MA Morgan FY Feng TS Lawrence, Nat Rev Cancer 2006 6 876 85 10.1038/nrc1953 17036041 (Pubitemid 44629899)
4. Predictive markers in breast and other cancers: a review. MJ Duffy, Clin Chem 2005 51 494 503 10.1373/clinchem.2004.046227 15637130 (Pubitemid 40300223)
5. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. N Takai A Jain N Kawamata LM Popoviciu JW Said S Whittaker I Miyakawa DB Agus HP Koeffler, Cancer 2005 104 2701 8 10.1002/cncr.21533 16265675 (Pubitemid 41798280)
6. Triple-negative breast cancer: clinical features and patterns of recurrence. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Nayod, Clin Cancer Res 2007 13 4429 34 10.1158/1078-0432. CCR-06-3045 17671126 (Pubitemid 47219710)
7. Fluorescence in situ hybridization: Gao CF. YK Wang, New technology and clinical laboratory diagnosis Beijing: People's Medical Publishing House 1 2010 85 112
8. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. YJ Bang E Van Cutsem A Feyereislova HC Chung L Shen A Sawaki F Lordick A Ohtsu Y Omuro T Satoh G Aprile E Kulikov J Hill M Lehle J Rüschoff YK Kang, Lancet 2010 376 687 97 10.1016/S0140-6736(10)61121-X 20728210
9. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. M Varella-Garcia J Diebold DA Eberhard K Geenen A Hirschmann M Kockx I Nagelmeier J Rüschoff M Schmitt S Arbogast F Cappuzzo, J Clin Pathol 2009 62 970 7 10.1136/jcp.2009.066548 19861557
10. Differential endocytic routing of homo and hetero-dimeric ErbB tyrosine kinases confers signalig superiority to receptor heterodimers. AE Lenferink R Pinkas-Kramarski ML van de Poll MJ van Vugt LN Klapper E Tzahar H Waterman M Sela EJ van Zoelen Y Yarden, EMBO J 1998 17 3385 3397 10.1093/emboj/17.12.3385 9628875 (Pubitemid 28279512)
11. HER1/EGFR targeting: refining the strategy. R Pérez-Soler, Oncologist 2004 9 58 67 10.1634/theoncologist.9-1-58 14755015 (Pubitemid 38134014)
12. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. K Sakai S Mori T Kawamoto S Taniguchi O Kobori Y Morioka T Kuroki K Kano, J Natl Cancer Inst 1986 77 1047 52 3464796 (Pubitemid 17184126)
13. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. J Brabender KD Danenberg R Metzger PM Schneider J Park S Salonga AH Hölscher PV Danenberg, Clin Cancer Res 2001 7 1850 5 11448895 (Pubitemid 32994816)
14. Assessment of HER2 status in breast cancer. F Penault-Llorea A Cayre, Bull Cancer 2004 91 211 15 15899610
15. Effect of gefitinib on radiosensitivity of gastric cancer cell lines. WG Cao T Ma JF Li H Li YB Ji XH Chen BY Liu YN Jin, Ai Zheng 2007 26 1330 5 18076795
16. Targeting EGF-receptor-signaling in squamous cell carcinomas of the head and neck. CW Reuter MA Morgan A Eckardt, Br J Cancer 2007 96 408 16 10.1038/sj.bjc.6603566 17224925 (Pubitemid 46215210)
17. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. A Onn AM Correa M Gilcrease T Isobe E Massarelli CD Bucana MS O'Reilly WK Hong IJ Fidler JB Putnam RS Herbst, Clin Cancer Res 2004 10 136 43 10.1158/1078-0432.CCR-0373-3 14734462 (Pubitemid 38114172)